



ALASKA BOARD OF PHARMACY MEETING

AGENDA (DRAFT)

FEBRUARY 15, 2024

Discussion of the following topics may require executive session. Only authorized members will be permitted to remain in the Board/Zoom room during executive session.

Meeting Details

Meeting Name: Alaska Board of Pharmacy Meeting
Meeting Start Time: 9:00 AM (AKST)
Meeting Start Date: February 15, 2024
Meeting End Time: 5:00 PM (AKST)
Meeting End Date: February 15, 2024
Meeting Locations: 1. Board/Staff - Suite 1560, Atwood Building, Anchorage, AK
2. Zoom for Public Attendees (Limited In-Person Space)

Meeting Registration Link:

<https://us02web.zoom.us/meeting/register/tZEtce2upz4sEtSIEtHRaUt3ipugZwQjIBH4>

Dial ID: 850 6469 5680

Passcode: 306014

Links

Board of Pharmacy Homepage: pharmacy.alaska.gov

Prescription Drug Monitoring Program State page: pdmp.alaska.gov

Board Members:

Ashley Schaber,
Pharmacist
(Chairperson)

James Henderson,
Pharmacist

Carla Hebert,
Pharmacist

Ramsey Bell,
Pharmacist

Sylvain Nouvion,
Pharmacist

Vacant, Pharmacy
Technician

Sara Rasmussen,
Public Member

Staff:

Michael Bowles,
Executive
Administrator

Brigham Perez,
Records and
Licensing
Supervisor

Amy Glenn,
Licensing
Examiner

Sarah Jones,
Licensing
Examiner

Upcoming Meetings:

April 11, 2024

August 22, 2024
(Tentative)

November 14, 2024
(Tentative)

Agenda

1. Roll Call/Call to Order (9:00 - 9:02)
2. Ethics Disclosures (9:02 – 9:03)
3. Consent Agenda Items (9:03 – 9:05)
 - Review/Approve Meeting Agenda
 - Review/Approve Previous Meeting Minutes
 - Review Lost or Stolen Controlled Substances/DEA 106s
 - Review Well Being Index
 - Applicability of USP reference in Food, Drug & Cosmetic Act Email
4. Investigations Review (9:05 – 10:00)
 - Holly Handley, Investigator
 - Introduction of New Investigator, Julienne Kim
 - Investigative Report
 - Case Reviews, Confidential - Executive Session
 - Application Denial – Executive Session
5. Board Business (10:00 – 11:45)
 - Application Reviews, Confidential - Executive Session
 - Review Strategic Plan
 - Non-Punitive Addiction Treatment Assistance with Self-Referral
 - Discuss the Way Forward on Just Culture
 - Disciplinary Matrix Update Discussion
 - Reporting Disciplinary Actions
 - Delegation of Authority to Executive Administrator for Disciplinary Decisions of Late Forms
 - Discuss Letter of Concern from Providers about Opioid Prescribing in Alaska
 - Discuss Past Disciplinary Action for Applicants
 - Committee Assignments
 - 2024 Conferences - Decide on NABP Delegate and Conference Attendees
 - April 01-04, 2024 – RX and Illicit Drug Summit (Atlanta, GA)
 - Sylvain Nouvion is attending this conference.

- May 14-17, 2024 – NABP Annual Meeting (Fort Worth, TX)
 - 2 Board Members
- September 13-14, 2024 – AKPhA Fall Health System Academy Conference (Girdwood, AK)
 - 1 Board Member
- October 20-23, 2024 – NABP District 6, 7, 8 Meeting (Albuquerque, NM)
 - 1 Board Member
- Tasks List Review and Update
- 6. Public Comment Period (11:45 – 12:00)
- 7. Industry Updates (12:00 – 12:30)
 - Alaska Pharmacists Association (AKPhA) – Brandy Seignemartin, PharmD
 - Alaska Department of Health – John Boston, DO, CMD
- 8. Adjourn for Lunch (12:30 – 1:00)
- 9. Roll Call/Call to Order (1:00 – 1:05)
- 10. Division Updates (1:05 – 2:00)
 - Pacifico National Dba AmEx Pharmacy Hearing and Recommendation Review (1:05 – 1:15)
 - Michael Bowles, Executive Administrator (1:15 – 1:30)
 - Introduction of new Records and Licensing Supervisor, Brigham Perez
 - Update on NABP MPJE Process Change
 - Update of Online Applications Project
 - Application Statistics
 - Lisa Sherrell, Prescription Drug Monitoring Program (PDMP) Manager (1:30 – 2:00)
 - PDMP Updates
- 11. Public Comment Period (2:00 – 2:15)
- 12. Statutes and Regulations (2:15 – 4:50)
 - Discuss Implementing Solutions Report
 - Statute Change Addressing Score Transfers
 - Discuss Language to Update PDMP to version 5.0
 - Clarify 12 AAC 52.020(f)
 - “Ownership” (at which level)
 - Clarify 12 AAC 52.235(a)(1)(C)

- The pharmacy uses software that displays the image or graphical description of the correct drug being verified; however, if there is any deviation between the image or graphical description and the actual product being distributed, a pharmacist must review and dispense the order.
 - Consider hospital technicians involved in this process.
 - Clarify 12 AAC 52.855(b)
 - Only pharmacists dispensing controlled substances should register.
 - Bring into alignment 12 AAC 52.698 - FDA Good Manufacturing Practices
 - Language under Manufacturer regulations should be the same as Outsourcing facilities, “submits the results of the most recent Good Manufacturing Practice (GMP) inspection by the United States Food and Drug Administration.”
 - Discuss 12 AAC 52.540
 - DEA 106 requirement clarification, does the board need to review these?
 - Align statutes and regulations with Pharmacist Intern vs Pharmacy Intern language
 - “Pharmacy Intern” is used 5 times in statute and 11 times in regulation. “Pharmacist Intern” is used 0 times in statute and 47 times in regulation.
 - Incorporation of USP 797 and 800 Into Regulation
 - Collaborative Practice Agreements
 - Should Board approval be a requirement or can these be kept at the physician/pharmacist level?
13. Chair Final Comments (4:50 – 5:00)
- Next Meeting Dates
14. Adjourn (5:00)